Regenemed, Inc.

San Diego, CA 92121

SBIR Award Summary

Total Number of Awards 9
Total Value of Awards $3.61MM
First Award Date 09/30/03
Most Recent Award Date 09/18/09

Key Personnel

Last Name Name Awards Contact
Naughton Brian A Naughton 9

9 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-02-075
Budget: 09/18/09 - 07/31/11

DESCRIPTION (provided by applicant): Under current regulatory policies, chemicals that are believed to comprise both a significant exposure and health risk in the human population are selected to undergo testing for toxicity and carcinogenic potency. The traditional method for evaluating carcinogenic activity and chronic toxicity of a specif...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-02-075
Budget: 09/18/09 - 07/31/11

DESCRIPTION (provided by applicant): Under current regulatory policies, chemicals that are believed to comprise both a significant exposure and health risk in the human population are selected to undergo testing for toxicity and carcinogenic potency. The traditional method for evaluating carcinogenic activity and chronic toxicity of a specif...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-02-75
Budget: 08/01/08 - 07/31/09

DESCRIPTION (provided by applicant): Under current regulatory policies, chemicals that are believed to comprise both a significant exposure and health risk in the human population are selected to undergo testing for toxicity and carcinogenic potency. The traditional method for evaluating carcinogenic activity and chronic toxicity of a specif...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-02-75
Budget: 08/01/07 - 07/31/08

DESCRIPTION (provided by applicant): Under current regulatory policies, chemicals that are believed to comprise both a significant exposure and health risk in the human population are selected to undergo testing for toxicity and carcinogenic potency. The traditional method for evaluating carcinogenic activity and chronic toxicity of a specif...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-02-75
Budget: 09/30/06 - 07/31/07

DESCRIPTION (provided by applicant): Under current regulatory policies, chemicals that are believed to comprise both a significant exposure and health risk in the human population are selected to undergo testing for toxicity and carcinogenic potency. The traditional method for evaluating carcinogenic activity and chronic toxicity of a specif...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-01-52
Budget: 09/30/04 - 09/30/06

DESCRIPTION (provided by applicant): The Hepatitis C virus (HCV) is a leading cause of liver disease for which current treatments are inadequate. Worldwide, 170 million are infected with HCV and the disease is projected to kill more people than AIDS within a few years based on a death rate that is likely to triple in the next 20 years. HCV infe...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-02-75
Budget: 04/01/04 - 09/29/06

DESCRIPTION (provided by applicant): Under current regulatory policies, chemicals that are believed to comprise both a significant exposure and health risk in the human population are selected to undergo testing for toxicity and carcinogenic potency. The traditional method for evaluating carcinogenic activity and chronic toxicity of a specif...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-02-75
Budget: 04/01/04 - 09/30/05

DESCRIPTION (provided by applicant): Under current regulatory policies, chemicals that are believed to comprise both a significant exposure and health risk in the human population are selected to undergo testing for toxicity and carcinogenic potency. The traditional method for evaluating carcinogenic activity and chronic toxicity of a specif...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-01-52
Budget: 09/30/03 - 09/29/04

DESCRIPTION (provided by applicant): The Hepatitis C virus (HCV) is a leading cause of liver disease for which current treatments are inadequate. Worldwide, 170 million are infected with HCV and the disease is projected to kill more people than AIDS within a few years based on a death rate that is likely to triple in the next 20 years. HCV infe...